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Chronic graft-versus-host disease (cGVHD) is a critical complication after allogeneic hematopoietic stem cell
transplantation. The conditioning therapy has been involved in the impairment of bone marrow (BM)
mesenchymal stem/stromal cells (MSCs). However, the potential implication of MSCs in the pathophysiology
of cGVHD has not been investigated. We analyzed expanded MSCs from patients with cGVHD and compared
them with those from transplantation patients without cGVHD. The MSCs from both groups were of host
origin and their reserves were comparable. They showed similar morphology, immunophenotype, population
doubling times, self-renewal capacity, differentiation, and migration potential. The immunomodulatory po-
tential of the 2 groups was also identical, they were both capable of inhibiting phytohemagglutinin-activated
peripheral blood mononuclear cells (PBMCs) proliferation and inducing regulatory T cells after coculturing
with CD4þ T cells, and the immunosuppressive factors were secreted similarly in both MSCs whether in
normal culture or coculture with PBMCs. No signiﬁcant differences were observed in the cellular senescence
and apoptosis between 2 groups. In addition, MSCs from patients with cGVHD displayed normal phenotype
and function compared with their counterparts from healthy donors, although reduced frequency in BM
mononuclear cell fraction was observed in these patients. Taken together, our results suggest that MSCs do
not seem to contribute to the pathogenesis of cGVHD and indicate the feasibility of autologous cell therapy in
patients who are not completely responding to standard immunosuppressive therapy for cGVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a major
complication after allogeneic hematopoietic stem cell
transplantation (HSCT) that causes signiﬁcant morbidity
and mortality, although some improvements have been
made using ﬁrst-line treatments [1-4]. In addition to prior
acute GVHD (aGVHD), some unique risk factors are thought
to correlate with cGVHD, including stem cell source [1,5]
and older recipient age [6]. cGVHD is known to have char-
acteristic clinical manifestations that resemble those
observed in autoimmune diseases. However, the patho-
physiology of cGVHD is complicated and still not completely
understood.edgments on page 1027.
equests: He Huang, 79 Qingchun Road,
hina 310003.
mail.com (H. Huang).
15.02.013
ty for Blood and Marrow Transplantation.Mesenchymal stem/stromal cells (MSCs) are multipotent
ﬁbroblast-like cells that can differentiate into osteoblasts,
chondrocytes, adipocytes, and myoblasts [7]. In addition,
such cells exhibit extensive immunomodulatory activities
and they affect a broad panel of immune cells of the innate
and adaptive immunity [8,9]. The mechanisms responsible
for MSCs immune regulation mainly involve direct cell-cell
contact and the release of soluble inducible factors, such as
transforming growth factor-b1 (TGF-b1), interleukin-10 (IL-
10), hepatocyte growth factor (HGF), and prostaglandin-E2
(PGE2) [8,10,11]. Given the immunomodulatory properties
of MSCs and dysregulated immune responses in cGVHD, it
could be hypothesized that MSCs might contribute to the
pathogenesis of cGVHD.
Due to low immunogenicity, allogeneicMSCswere largely
utilized in clinical settings. However, allogeneic MSCs were
also found to be susceptible for lysis by cytotoxic CD8þ T cells
[12] and immune rejected by MHC-mismatched recipients
[13]. Autologous MSCs may thus be the preferable candidate
Table 1
Clinical Characteristics of Patients
cGVHD
(n ¼ 25)
No cGVHD
(n ¼ 16)
P Value
Age, median (range), yr 26 (14-48) 28 (18-52) NS
Sex (male/female) 18/7 12/4 NS
Diagnosis NS
Acute myeloid leukemia 10 8
Acute lymphoblastic leukemia 9 8
Chronic myeloid leukemia 4 0
Non-Hodgkin lymphoma 2 0
Source of HSC NS
PB 23 15
BM 2 1
Donor .005
Related 19 5
Unrelated 6 11
HLA .018
Matched 11 13
Mismatched 14 3
Acute GVHD grade II to IV 11 2 .034
Time after HSCT, median
(range), mo
20 (11-67) 23 (11-93) NS
Immunosuppressive drugs 22 7 .007
cGVHD grade
Mild 17 0
Moderate 7 0
Severe 1 0
NS indicates not signiﬁcant; HSC, hematopoietic stem cells; PB, peripheral
blood.
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with Crohn’s disease and systemic sclerosis were not affected
and could be considered in an autologous setting [14,15],
whereas MSCs in patients with some other autoimmune
diseases were impaired [16-18]. Another issue is whether
MSCs derived from cGVHD patients are suitable for autolo-
gous cell therapy. However, the biological properties of MSCs
in cGVHD patients have not been studied.
In this study, we investigated whether MSCs expanded
from patients with or without cGVHD showed any differ-
ences concerning the reserves and proliferation, differenti-
ation, immunomodulation, and migration potential.
Furthermore, phenotypical and functional characterization
of cGVHD patients derived MSCs were compared with
normal counterparts isolated from healthy individuals.MATERIALS AND METHODS
Patients
Bone marrow (BM) samples from 25 patients with cGVHD and 16 pa-
tients without cGVHD after allogeneic HSCT were studied. Detailed patient
characteristics are summarized in Table 1. The severity of cGVHD was clas-
siﬁed according to the National Institutes of Health consensus criteria [19].
Nineteen normal BM samples were obtained from age- and sex-matched
healthy individuals. Written informed consent was obtained from all sub-
jects before sample collection, and the study was approved by the local
ethics committee.Isolation, Culture, and Expansion of MSCs
BM mononuclear cells (BMMNC) were prepared from BM aspirates by
density gradient centrifugation and cultured in low-glucose Dulbecco’s
modiﬁed Eagle’s medium (Gibco, Invitrogen, Paisley, UK) supplemented
with 10% fetal bovine serum (FBS; Gibco) and penicillin/streptomycin [20].
When they reached 80% conﬂuence, MSCs were trypsinized and reseeded
at 8  103 cells/cm2. Passage (P) 3 to 5 MSCs were used for most experi-
ments. Further details are provided in the Supplementary Methods.MSC Frequency in the BMMNC Fraction
The assay for colony-forming unit ﬁbroblasts (CFU-F) was used to
calculate MSC frequency within the BMMNC fraction [15,21]. Brieﬂy,
BMMNC were seeded at 1 105 cells/well in 6-well plates and expanded for14 days. The clonogenic efﬁciency was calculated as the number of colonies
per 106 BMMNC seeded.
Characterization of MSCs
MSC origin, immunophenotype, self-renewal, differentiation potential,
senescence, apoptosis, and migration potential were studied. The detailed
information is described in the Supplementary Methods.
Immunosuppressive Properties of MSCs
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy
volunteers and labeled with 5 mM carboxyﬂuorescein diacetate succinimidyl
ester (Invitrogen). Labeled PBMCs were then stimulated with 2 ug/mL
phytohemagglutinin (PHA, Sigma, St. Louis, MO) in the presence or absence
of MSCs at different ratios. After 5 days, carboxyﬂuorescein diacetate suc-
cinimidyl esterelabeled cells were harvested and analyzed for cell division
by ﬂow cytometry.
Supernatants from cultures of MSCs or cocultures of MSCs/PBMCs were
collected and cytokines were measured using commercially available
enzyme-linked immunosorbent assay (ELISA) kits: TGF-b1, IL-10, HGF,
(eBioscience, San Diego, CA), and PGE2 (Cayman Chemical, Ann Arbor, MI).
For inducing regulatory T cells (Tregs), MSCs were cocultured with pu-
riﬁed CD4þ Tcell for 5 days, then nonadherent cells were separated from the
MSCs and evaluated for the proportion of Tregs present by ﬂow cytometry
using monoclonal antibodies speciﬁc to CD4-FITC (BD Pharmingen, San
Diego, CA), CD25-PE, CD127-APC (Biolegend, San Diego, CA). Further details
are provided in the Supplementary Methods.
Real-time Quantitative Polymerase Chain Reaction Analysis
Total RNA was extracted from MSCs using Trizol reagent (Invitrogen)
and reverse transcribed into complementary DNA (cDNA) using PrimeScript
RT reagent Kit (Takara, Dalian, China). Quantitative polymerase chain reac-
tion (qPCR) was performed in a LightCycler system (Roche, Basel,
Switzerland) using SYBR Premix Ex Taq (Takara). Each sample was per-
formed in triplicate and all results were normalized to the expression of
glyceraldehydes 3-phosphate dehydrogenase (GAPDH). Primer sequences
are provided in the Supplementary Methods.
Statistical Analysis
Data are expressed as mean  standard error of the mean (SEM). The
results were compared using one-way ANOVAwith Fisher’s least signiﬁcant
difference post hoc test and Student’s t-test (SPSS 18.0 statistical software).
Statistical signiﬁcance was deﬁned as P value of < .05.
RESULTS
Origin of MSCs in Patients after Allogeneic HSCT
BM MSCs were successfully expanded from all patients
and healthy donors. To study chimerism of MSCs derived
from patients after allogeneic HSCT, P4 cells from 10 patients
(5 with cGVHD, 5 without cGVHD) were analyzed. Although
PBMCs chimerism was donor type, MSCs in all patients
remained of host origin whether the patients had cGVHD or
not (Supplementary Figure 1). Time after transplantation did
not have any inﬂuence onMSC origin, nor was any difference
observed between patients receiving BM and peripheral
blood grafts.
Characterization of BM MSCs
MSCs from healthy donors (HD-MSC) and patients with
cGVHD (cGVHD-MSC) or without cGVHD (no cGVHD-MSC)
displayed a similar spindle-shape morphology (Figure 1A).
The immunophenotype of cells was analyzed by ﬂow
cytometry. All MSCs highly expressed CD73, CD90, and
CD105 and moderately expressed HLA-ABC, they were
negative for CD34, CD45, CD11b, CD19, and HLA-DR
(Figure 1B). As determined by CFU-F assay, the frequency of
cGVHD-MSC (n ¼ 16) was signiﬁcantly lower than HD-MSC
(n ¼ 12) (19.93  3.73/106 BMMNC and 45.92  10.21/106
BMMNC, respectively; P < .01). The frequency of no cGVHD-
MSC (23.52  6.57/106 BMMNC; n ¼ 9) was also lower than
HD-MSC (P < .05), probably due to the inﬂuence of pre-
conditioning treatment before HSCT. However, there was no
Figure 1. Morphology, immunophenotype and reserves of MSCs. (A) Representative morphology of HD-MSC (left), no cGVHD-MSC (middle), and cGVHD-MSC (right).
Scale bar ¼ 100 mm. (B) Representative ﬂow cytometric characterization of cell surface markers expression on MSCs. Gray ﬁlled histograms depict the expression of
CD73, CD90, CD105, HLA-ABC, and the absence of CD34, CD45, CD11b, CD19, and HLA-DR. Isotypic controls are represented by the open histograms. (C) Comparison of
MSC frequency within the BMMNC fraction. Values represent the mean ( SEM) number of CFU-F per 106 BMMNC. *P < .05, **P < .01. HD indicates healthy donors;
cGVHD, chronic graft-versus-host disease; BMMNC, bone marrow mononuclear cells; CFU-F, colony-forming unit ﬁbroblasts; SEM, standard error of the mean.
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and no cGVHD-MSC (Figure 1C).
MSC Proliferation, Self-renewal, and Differentiation
Potential
The proliferation potential of MSCs was evaluated by
detecting the population doubling time from P1 to P5. As
indicated in Figure 2A, no differences were observed in HD-
MSC (n¼ 14), no cGVHD-MSC (n¼ 13), and cGVHD-MSC (n¼
15) in each passage. In detail, the doubling time ranged from
3.57  .27 (P1) to 6.73  .61 (P5) days in HD-MSC, from 3.08
 .25 (P1) to 6.66  1.20 (P5) days in no cGVHD-MSC, and
from 3.36  .29 (P1) to 7.04  1.38 (P5) days in cGVHD-MSC.
In addition, we examined whether the self-renewal capacity
of MSCs from cGVHD patients was impaired. Oct4, Sox2, and
Nanog were reported to be essential for pluripotency and
self-renewal of not only embryonic stem cells but also so-
matic stem cells such as MSCs [22,23]. We showed that the
expression level of these pluripotency-associated genes in
cGVHD-MSC (n ¼ 12) was comparable to no cGVHD-MSC
(n ¼ 7) and HD-MSC (n ¼ 8) (Figure 2B).
To assess the differentiation potential of MSCs, we
induced the in vitro differentiation of HD-MSC (n ¼ 12), no
cGVHD-MSC (n ¼ 7), and cGVHD-MSC (n ¼ 13) intoosteogenic and adipogenic lineages. After induction for 14
days, all MSCs displayed similar osteogenic and adipogenic
differentiation capacity as demonstrated by detection of
calciﬁed deposits with alizarin red staining and lipid droplets
with oil red O staining respectively (Figure 2C). The expres-
sion of speciﬁc marker genes was further investigated using
real-time qPCR. Osteogenic markers RUNX2 and IBSP were
expressed almost identical in all MSCs (Figure 2D). The
expression of adipogenic markers PPAR-g and FABP4 were
found less in no cGVHD-MSC and cGVHD-MSC compared
with HD-MSC (Figure 2D). The differences, however, did not
reach statistical signiﬁcance.
Senescence and Apoptosis of MSCs
To evaluate senescence of MSCs, we employed
senescence-associated b-galactosidase (SA-b-Gal) as a
marker. As shown in Figure 3A and B, the percentage of SA-b-
Galepositive cells in cGVHD-MSC (9.43%  1.14%; n ¼ 22)
was similar to no cGVHD-MSC (10.71%  1.78%; n ¼ 13) and
HD-MSC (7.81%  1.01%; n ¼ 17). We also assessed the p53,
p21, and p16 expression level in MSCs: consistent with the
SA-b-Gal staining results, these senescent phenotype asso-
ciated markers were without signiﬁcant differences in all
MSCs (Figure 3C). Furthermore, the telomere length of
Figure 2. Proliferation, self-renewal, and differentiation potential of MSCs. (A) Population doubling time of MSCs from P1 to P5. (B) Mean relative values ( SEM) of
Oct4, Sox2 and Nanog gene expression in MSCs. (C) Osteogenic differentiation (upper panel) of HD-MSC (left), no cGVHD-MSC (middle) and cGVHD-MSC (right) was
demonstrated by alizarin red staining, adipogenic differentiation (lower panel) of HD-MSC (left), no cGVHD-MSC (middle) and cGVHD-MSC (right) was detected by oil
red O staining. Scale bar ¼ 100 mm. (D) Gene expression measured by real-time qPCR of osteogenic markers RUNX2, IBSP (left) and adipogenic markers PPAR-g, FABP4
(right). P1-P5, passage numbers; RUNX2, runt-related transcription factor 2; IBSP, integrin-binding sialoprotein; PPAR-g, peroxisome proliferator-activated receptor-g;
FABP4, fatty acid binding protein 4; qPCR, quantitative polymerase chain reaction.
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ﬂow cytometry ﬂuorescence in situ hybridization and no
differences were observed (data not shown).
We next investigated the apoptosis of MSCs using
Annexin V-FITC/PI staining. The percentage of apoptotic cells
in cGVHD-MSC (4.88%  .49%; n ¼ 10) was comparable in
contrast to no cGVHD-MSC (4.52%  .71%; n ¼ 6) and HD-
MSC (5.32%  .31%; n ¼ 7) (Figure 3D,E).
Immunomodulatory Potential of MSCs
To investigate whether MSCs from cGVHD patients pre-
serve immunosuppressive capacity, the effect of inhibiting
the proliferation of PHA-activated PBMCs was evaluated.
MSCs were mixed with allogeneic PBMCs at 5 different ratios
(1:2.5, 1:5, 1:10, 1:20, and 1:40). cGVHD-MSC (n ¼ 7)
signiﬁcantly reduced the proliferative response of PBMCs in a
dose-dependent manner (Figure 4A). No signiﬁcant differ-
ences were observed compared with no cGVHD-MSC (n ¼ 7)
and HD-MSC (n ¼ 5).
Moreover, we assessed the capacity of cGVHD-MSC to
induce Tregs in puriﬁed CD4þ T cells. After coculturing withCD4þ T cells for 5 days, cGVHD-MSC (n ¼ 9) signiﬁcantly
increased the percentage of CD4þCD25hi cells comparedwith
CD4þ control cells (n ¼ 4) (5.92%  .31% and 3.48%  .65%,
respectively; P < .01). Similar results were obtained in no
cGVHD-MSC (6.01%  .48%; P < .01; n ¼ 7) and HD-MSC
(6.40%  .15%; P < .01; n ¼ 5) (Figure 4B,C). The proportion
of CD25hiCD127 cells was also increased by cGVHD-MSC
(3.35%  .13%), no cGVHD-MSC (3.41%  .13%), and HD-MSC
(3.43%  .18%) compared with CD4þ control cells (1.55% 
.18%; P < .01 for all MSC populations versus control cells).
There were no apparent differences in all MSC populations
(Figure 4D,E).
Previous studies revealed that the release of some cyto-
kines was associated with the immunosuppressive effect of
MSCs [8,10,11], we then detected the TGF-b1, IL-10, HGF, and
PGE2 levels in supernatants of MSC culture or MSC/PBMC
coculture. As shown in Figure 4F, the capacity of MSCs to
respond to inﬂammatory stimuli was different. Although all
cocultures increased the production of IL-10 and PGE2
compared with MSC cultures, only no cGVHD-MSC/PBMC
coculture and cGVHD-MSC/PBMC coculture could increase
Figure 3. Cellular senescence and apoptosis in MSCs. (A) Representative SA-b-Gal activity in HD-MSC, no cGVHD-MSC and cGVHD-MSC. Scale bar ¼ 100mm. (B)
Percentage of SA-b-Gal positive cells were quantiﬁed in all MSC populations. Data are presented as mean  SEM. (C) mRNA expression of p53, p21 and p16 in HD-MSC
(n ¼ 5), no cGVHD (n ¼ 9), and cGVHD-MSC (n ¼ 10). (D) Representative apoptosis analysis in MSCs by ﬂow cytometry. (E) Percentage of Annexin-V positive cells
(mean  SEM) were quantiﬁed and showed in histograms. SA-b-Gal, senescence-associated b-galactosidase.
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increased the production of TGF-b1. However, all MSCs
secreted similar levels of these cytokines whether in MSCculture or MSC/PBMC coculture, except PGE2, which was
secreted at lower levels in no cGVHD-MSC/PBMC coculture
compared with HD-MSC/PBMC coculture (P < .05).
Figure 4. Immunoregulatory functions of MSCs. (A) Inhibitory effect of HD-MSC, no cGVHD-MSC and cGVHD-MSC on proliferation of PHA-activated PMBCs. PBMCs
were cultured in the absence or presence of different number of MSCs. (B,D) Representative dot plots showing the percentage of CD4þCD25hi cells (B) and the
percentage of CD25hiCD127 cells in the gate of CD4þ cells (D). (C,E) Cumulative data showing the mean ( SEM) proportion of CD4þCD25hi cells (C) and
CD25hiCD127 cells (E). (F) The cytokines in supernatants of HD-MSC (n ¼ 5), no cGVHD-MSC (n ¼ 7), cGVHD-MSC (n ¼ 12) single culture, and MSC/PBMC coculture
were assayed by ELISA. Data are expressed as mean  SEM. *P < 0.05, **P < .01. PHA, phytohemagglutinin; TGF-b1, transforming growth factor-b1; IL-10, interleukin-
10; HGF, hepatocyte growth factor; PGE2, prostaglandin-E2; ELISA, enzyme-linked immunosorbent assay.
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It has been demonstrated that MSCs could migrate to the
injured tissues and participate in tissue repair [24,25]. To
investigate whether the migration capacity of cGVHD-MSC
was reduced, we employed the transwell migration assay
and counted the number of cells on the lower side of
membrane. The results showed that the number of migrated
cells of cGVHD-MSC (228.82  22.94/ﬁeld; n ¼ 21) was
comparable to that observed for no cGVHD-MSC (234.39 29.63/ﬁeld; n ¼ 13) and HD-MSC (268.58  18.76/ﬁeld;
n ¼ 16) (Supplementary Figure 2A,B).
DISCUSSION
cGVHD is characterized by alloreactive and autoreactive
phenomena with multiple organ involvement [1-3]. As an
important immunomodulatory cell subset, the abnormalities
of MSCs have been reported to play a role in the pathogenesis
of several autoimmune diseases [17,18]. In this study, we
B. Wang et al. / Biol Blood Marrow Transplant 21 (2015) 1020e10281026aimed to explore whether MSCs from cGVHD patients were
affected, which, in turn, might contribute to the pathogenesis
and development of the disease. Thus, the quantitative,
phenotypical, and functional characteristics of MSCs derived
from patients with or without cGVHD were compared. A
comparative analysis of patients and healthy donors was also
described.
MSCs could be readily isolated from BM of all patients
with or without cGVHD assayed in the study. The
morphology and immunophenotype of MSCs from both pa-
tients were indistinguishable from the counterparts of
healthy donors, and they displayed normal osteogenic and
adipogenic differentiation. The origin of MSCs in patients
after allogeneic HSCT was analyzed using PCR-STR assay.
Although MSCs were found mixed in mobilized peripheral
blood stem cells and could engraft into BM of recipients after
allogeneic transplantation [26], most studies have indicated
that MSCs remain of host origin regardless of the graft
source, conditioning regimen, and the time interval between
transplantation and detection [27,28]. In agreement with
these studies, our results showed that post-transplantation
chimerism of BM-derived MSCs was host type regardless of
the cGVHD complication, whereas PBMCs were observed of
donor origin.
The host origin of MSCs after allogeneic HSCT may reﬂect
their relative resistance to conditioning therapy. However,
whether the reserves of MSCs in patients with or without
cGVHD were differentially affected by previous conditioning
therapy was unknown. In our study, all patients were
executed myeloablative conditioning regimen. CFU-F assay
results indicated that the frequency of MSCs within the
BMMNC fraction was similar between the patients, sug-
gesting that abnormal MSC number seems unlikely to un-
derlie the cGVHD pathogenesis. Nevertheless, the MSC
reserves in both patients were signiﬁcantly reduced in
comparison to healthy donors. Although MSC reserves vary
in hematological disorders, high-dose chemotherapeutic
agents used in HSCT may be the main reason of MSC damage
[29,30].
The proliferation potential of MSCs was estimated in
terms of population doubling time [20]. Despite of the
reduced frequency, MSCs from both patients displayed a
similar proliferative capacity compared with healthy donors.
These results are in accordance with previous data from
mouse model [30]. No difference about proliferation rate
over passages was observed between patients with or
without cGVHD as well. Furthermore, we have shown
normal self-renewal ability of cGVHD-derived MSCs by
detecting the pluripotency-associated genes expression.
Chemotherapeutic agents have been reported to induce
MSCs senescence in vitro [31]. However, our results showed
that cellular senescence in post-transplantation patients was
not signiﬁcantly different from healthy donors. There were
also no differences between 2 patient groups. Regarding the
survival characteristics, we have shown similar apoptotic
rates in all MSCs, which suggests that MSC apoptosis seems
to be of no importance in the observed low frequency of CFU-
F in patients after allogeneic HSCT.
Because abnormal immune responses have been associ-
ated with the pathogenesis of cGVHD [3,32], we investigated
whether an impaired immunomodulation of MSCs played a
role. However, our results demonstrated that MSCs from
cGVHD patients signiﬁcantly suppressed the proliferation of
PHA-activated PBMCs in a dose-dependent manner. The
suppressive effect was highly similar to MSCs derived frompatients without cGVHD and healthy donors. Soluble factors
such as TGF-b1, IL-10, HGF, and PGE2 have been reported to
play important roles in immunomodulatory effects of MSCs
[8,10,11]. We, thus, detected the expression of these factors
and found that all MSCs released almost similar amounts not
only in normal culture but also in coculture with PBMCs,
further suggesting the intact immunosuppressive capacity of
cGVHD-derived MSCs.
MSCs have been shown to be able to induce Tregs in vitro
and in vivo [33-35], mainly depending on cell contact and
soluble factors including TGF-b1 and PGE2 [10,34]. In pa-
tients with cGVHD, it has been demonstrated that reduced
frequency of Tregs was implicated in spite of their normal
regulatory function [36-38]. Conﬂicting results were also
reported, which indicated an increased number of suppres-
sive Tregs in these patients [39,40]. We then evaluated
whether MSCs derived from cGVHD patients could normally
induce Tregs. The proportion of CD4þCD25hiCD127 Tregs
was obviously increased by coculturing with cGVHD-derived
MSCs compared with CD4þ control cells. The effect of
inducing Tregs did not differ from MSCs derived from pa-
tients without cGVHD and healthy donors. These results
suggested that MSCs preserve their immunomodulatory
properties and do not account for the immune dysfunction in
cGVHD patients.
MSC migration is believed to play a pivotal role in MSC-
mediated tissue repair: both endogenous and exogenously
delivered MSCs were reported to migrate to damaged sites
[24,25,41,42]. We assessed the migration capacity of MSCs
in vitro, and no signiﬁcant differences were observed among
MSCs derived from different patients and healthy donors in
terms of migration rates.
Despite the small number of patients with moderate or
severe cGVHD, we observed that MSCs from these patients
displayed similar phenotype and function as those frommild
cGVHD patients (data not shown). This, to some extent, in-
dicates that MSCs are not associated with severity of cGVHD.
As MSCs have been employed to treat cGVHD efﬁcaciously
[43,44], it may be feasible to use autologous MSCs for ther-
apeutic applications in patients with refractory cGVHD.
However, whether MSC therapy should employ the alloge-
neic or autologous origin is controversial. Allogeneic MSCs
have a number of advantages, as they can be generated in
bulk and served as an off-the-shelf product so that patients
may receive the treatment without delay, whereas their use
has some restrictions. It has been demonstrated that allo-
geneic MSCs are immunogenic and rejected by MHC-
mismatched recipients [13,45]. The absence of donor MSCs
after allogeneic bone marrow transplantation also suggests
their incapacity of long-term engraftment [28]. Regarding
autologous MSCs for treating cGVHD, we have demonstrated
their normal immunosuppressive function and migration
potential, which are important to exert therapeutic effects. In
addition, unaffected proliferative capacity enables cGVHD-
derived MSCs to transplant with sufﬁcient quantity. How-
ever, it is worth noting that molecular and functional deﬁcits
of MSCs were observed in partial hematological malignant
diseases before allogeneic HSCT, although the abnormalities
were inconsistent [46,47]. In our study, most of patients have
experienced acute myeloid leukemia and acute lympho-
blastic leukemia. The data presented partially disagree with
previous reports suggesting that acute myeloid leuke-
miaederived MSCs are phenotypically and functionally
aberrant [48,49]. The discrepancy might be attributed to the
differences in methodology or the improved tumor
B. Wang et al. / Biol Blood Marrow Transplant 21 (2015) 1020e1028 1027microenvironment. Taking all of the available evidence into
consideration, it seems likely that MSCs derived from partial
cGVHD patients whose cells were not affected before HSCT
are recommended for autologous therapy. Further studies
will be required to assess the MSC characterization in various
diseases followed by HSCT.
In summary, the present study shows for the ﬁrst time, to
our knowledge, that BM MSCs from cGVHD patients exhibit
high similarity to MSCs from transplantation patients
without cGVHD in terms of number, proliferation potential,
differentiation potential, immunomodulatory properties,
and migration capacity. These results suggest that MSCs may
not be associated with the pathophysiology of cGVHD.
Furthermore, cGVHD-derived MSCs do not differ phenotyp-
ically and functionally from their normal counterparts except
for cell reserves. They do not show any aberrations in the
cellular senescence and apoptosis, either. Our ﬁndings give
some support to the potential use of autologous MSCs to
ameliorate cGVHD in patients who are resistant to regular
immunotherapy.
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